相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon
Hamed Laroui et al.
BIOMATERIALS (2011)
Adalimumab in ulcerative colitis: hypes and hopes
Gionata Fiorino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis
Luca Semerano et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Anti-Tumor Necrosis Factor-alpha Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner
Anne Christine W. Vos et al.
GASTROENTEROLOGY (2011)
Interactions Between the Host Innate Immune System and Microbes in Inflammatory Bowel Disease
Clara Abraham et al.
GASTROENTEROLOGY (2011)
Macrophages from IBD patients exhibit defective tumour necrosis factor-α secretion but otherwise normal or augmented pro-inflammatory responses to infection
Nair Campos et al.
IMMUNOBIOLOGY (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Inflammatory Bowel Disease
Arthur Kaser et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Is There an Increased Risk of Lymphoma and Malignancies Under Anti-TNF Therapy in IBD?
P. L. Lakatos et al.
CURRENT DRUG TARGETS (2010)
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
William J. Sandborn et al.
GUT (2010)
Biological therapies of inflammatory bowel disease
Aiping Bai et al.
IMMUNOTHERAPY (2010)
Randomized, Double-Blind, Placebo-Controlled Trial of the Oral Interleukin-12/23 Inhibitor Apilimod Mesylate for Treatment of Active Crohn's Disease
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2010)
Fontolizumab in Moderate to Severe Crohn's Disease: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2010)
Homing of Immune Cells: Role in Homeostasis and Intestinal Inflammation
Ailsa L. Hart et al.
INFLAMMATORY BOWEL DISEASES (2010)
Predictive Value of Epithelial Gene Expression Profiles for Response to Infliximab in Crohn's Disease
Ingrid Arijs et al.
INFLAMMATORY BOWEL DISEASES (2010)
IL-6: from its discovery to clinical applications
Tadamitsu Kishimoto
INTERNATIONAL IMMUNOLOGY (2010)
Abnormalities in the Handling of Intracellular Bacteria in Crohn's Disease
Pierre Lapaquette et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2010)
More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer
Tracy Putoczki et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry
Leonardo H. Travassos et al.
NATURE IMMUNOLOGY (2010)
Molecular Reclassification of Crohn's Disease by Cluster Analysis of Genetic Variants
Isabelle Cleynen et al.
PLOS ONE (2010)
The regulation of IL-10 production by immune cells
Margarida Saraiva et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease
Gary P. Toedter et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Actobiotics (TM) as a Novel Method for Cytokine Delivery The Interleukin-10 Case
Lothar Steidler et al.
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS (2009)
Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases
Michael Elliott et al.
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS (2009)
IL-23 and Autoimmunity: New Insights into the Pathogenesis of Inflammatory Bowel Disease
Clara Abraham et al.
ANNUAL REVIEW OF MEDICINE (2009)
Autophagy, Immunity, and Microbial Adaptations
Vojo Deretic et al.
CELL HOST & MICROBE (2009)
Biological Therapies for Inflammatory Bowel Diseases
Paul Rutgeerts et al.
GASTROENTEROLOGY (2009)
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
I. Arijs et al.
GUT (2009)
Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease
Andrew M. Smith et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Anti-adhesion molecule therapies in inflammatory bowel disease: Touch and go
Tommaso Stefanelli et al.
AUTOIMMUNITY REVIEWS (2008)
A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease - Exploring a new mechanism of action
Tim Bourne et al.
BIODRUGS (2008)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Interleukin-2 in the development and control of inflammatory disease
Katrina K. Hoyer et al.
IMMUNOLOGICAL REVIEWS (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis
N. Viget et al.
GUT (2008)
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease
S. Kugathasan et al.
GUT (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
G. Van Assche et al.
GUT (2006)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease
W. Reinisch et al.
GUT (2006)
Onercept for moderate-to-severe Crohn's disease: A randomized, double-blind, placebo-controlled trial
Paul Rutgeerts et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease
Robert Burakoff et al.
INFLAMMATORY BOWEL DISEASES (2006)
Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease
TJ Creed et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease
KR Herllinger et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohn's disease:: a randomized, double-blind, placebo-controlled trial
BG Feagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Review article: infliximab therapy for inflammatory bowel disease - seven years on
P Rutgeerts et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
A phase I trial with Transgenic bacteria expressing interleukin-10 in Crohn's disease
Henri Braat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
J Silverman et al.
NATURE BIOTECHNOLOGY (2005)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Tumor necrosis factor family members and inflammatory bowel disease
J Wang et al.
IMMUNOLOGICAL REVIEWS (2005)
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
H Ito et al.
GASTROENTEROLOGY (2004)
Functional expression of the interleukin-11 receptor α-chain and evidence of antiapoptotic effects in human colonic epithelial cells
S Kiessling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Anti-interleukin-12 antibody for active Crohn's disease
PJ Mannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease
A Di Sabatino et al.
GUT (2004)
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn's disease:: a randomised, double blind, placebo controlled trial
WJ Sandborn et al.
GUT (2004)
Protective strategies against ischemic injury of the liver
N Selzner et al.
GASTROENTEROLOGY (2003)
Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis
TJ Creed et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Anatomical basis of tolerance and immunity to intestinal antigens
AM Mowat
NATURE REVIEWS IMMUNOLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis
G Van Assche et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
T ten Hove et al.
GUT (2002)
Randomized, controlled trial of recombinant: human interleukin-11 in patients with active Crohn's disease
BE Sands et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
A Lügering et al.
GASTROENTEROLOGY (2001)
Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
JF Colombel et al.
GUT (2001)
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
SA Jones et al.
FASEB JOURNAL (2001)
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2000)
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
RN Fedorak et al.
GASTROENTEROLOGY (2000)
分享论文
